Research programme: monoclonal T-cell receptors based therapeutics - Immunocore

Drug Profile

Research programme: monoclonal T-cell receptors based therapeutics - Immunocore

Alternative Names: HCV-ImmTAC; Her2-ImmTAC; HIV-ImmTAC; IMC C103C; IMC D104C; IMC-mage1; ImmTACs; ImmTAV; Islet cell-ImmTAC; MAGE-A3-ImmTAC; NY-ESO-1-ImmTAC

Latest Information Update: 13 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunocore
  • Class Monoclonal antibodies; Proteins
  • Mechanism of Action Cytokine modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Hepatitis C; HIV infections; Type 1 diabetes mellitus

Most Recent Events

  • 08 Jun 2016 Pharmacodynamics data from a preclinical study released by Immunocore
  • 03 Mar 2014 Preclinical development is ongoing in the United Kingdom
  • 06 Apr 2011 Pharmacodynamics data from a Preclinical trial in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top